High Resolution CZT SPECT System Wins Commercial Innovation of the Year at WMIC 2025

[October, 2025]

London, Canada  – Scintica is proud to announce that the MH3D Alpha-SPECT Mini™, designed to accelerate theranostics and radioligand therapy research, was showcased during the Opening Ceremonies of the World Molecular Imaging Congress (WMIC) 2025—and went on to win the prestigious Commercial Innovation of the Year Award. 

Dr. Aileen Ouyang, Senior Scientist and Director of Regulatory Affairs at MH3D Inc., presented the abstract “Total-Body and Microscopic Mapping of Therapeutic Radionuclides in Small Animals Using the Alpha-SPECT Mini System.” Her presentation highlighted the unique capabilities of this next-generation preclinical SPECT imaging system, which was designed to address current gaps in radiopharmaceutical research by enabling both total-body and microscopic mapping of therapeutic radionuclides. 

After presenting alongside two other finalists, Dr. Ouyang was voted by the audience as the winner of the 2025 Commercial Innovation of the Year Award, underscoring the impact and promise of the Alpha-SPECT Mini™ system in advancing preclinical imaging. 

The Alpha-SPECT Mini™ employs advanced cadmium zinc telluride (CZT) detectors and a dual-field of view aperture, making it possible to: 

• Quantify the biodistribution of alpha- and beta-emitting radiopharmaceuticals with high precision. 

• Perform simultaneous mapping of multiple radioisotopes with closely located emission energies. 

• Maintain high sensitivity and spatial resolution for dynamic kinetic studies. 

• Seamlessly integrate with CT for multimodal imaging in preclinical drug development.

Dr. Ouyang’s research included four in vivo and ex vivo studies using isotopes such as 225Ac, 177Lu, 198Au, and 223Ra, demonstrating the Alpha-SPECT Mini’s ability to capture detailed organ-level distributions across the liver, kidneys, bladder, spinal vertebrae, and brain. 

About the Presenter 

Aileen Ouyang, Ph.D. serves as Senior Scientist and Director of Regulatory Affairs at MH3D Inc., where she leads efforts to bring preclinical SPECT imaging systems to the market. She earned her Ph.D. from the University of Michigan, focusing on advanced biomedical technologies. Her work bridges academic innovation and clinical translation, with a focus on intelligent, responsive imaging solutions.